{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:11:26Z","timestamp":1790892686428,"version":"4.1.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/ftd.0b013e31823cdec9","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T01:24:05Z","timestamp":1325294645000},"page":"85-97","source":"Crossref","is-referenced-by-count":56,"title":["The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic Myeloid Leukemia and Metastatic or Unresectable Gastrointestinal Stromal Tumors"],"prefix":"10.1097","volume":"34","author":[{"given":"Jennifer F T","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent H","family":"Mabasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary H H","family":"Ensom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib.","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemiaadvances in biology and new approaches to treatment.","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2005.40709.x","article-title":"The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.","volume":"100","author":"Tran","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-14-20210129","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors.","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-14-20210129","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"R14-14-20210129","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","article-title":"Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis.","volume":"23","author":"Gambacorti-Passerini","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","article-title":"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.","volume":"53","author":"Bolton","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-14-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.","volume":"55","author":"Takahashi","year":"2010","journal-title":"J Hum Genet"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.","volume":"88","author":"Takahashi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R24-14-20210129","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","article-title":"Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study.","volume":"101","author":"Ishikawa","year":"2010","journal-title":"Cancer Sci"},{"key":"R25-14-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003088-199834040-00001","article-title":"Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?","volume":"34","author":"Ensom","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R26-14-20210129","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"OBrien","year":"2003","journal-title":"N Engl J Med"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R28-14-20210129","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"R29-14-20210129","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"R30-14-20210129","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R31-14-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","article-title":"Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.","volume":"60","author":"Schmidli","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R32-14-20210129","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.","volume":"98","author":"Widmer","year":"2008","journal-title":"Br J Cancer"},{"key":"R33-14-20210129","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.leukres.2009.12.009","article-title":"Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.","volume":"34","author":"Widmer","year":"2010","journal-title":"Leuk Res"},{"key":"R34-14-20210129","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jchromb.2004.01.032","article-title":"Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples.","volume":"804","author":"Velpandian","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R35-14-20210129","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":"Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.","volume":"27","author":"Titier","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R36-14-20210129","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.","volume":"877","author":"Haouala","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R37-14-20210129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.leukres.2009.11.009","article-title":"Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.","volume":"34","author":"Davies","year":"2010","journal-title":"Leuk Res"},{"key":"R38-14-20210129","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.","volume":"877","author":"De Francia","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R39-14-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1570-0232(01)00611-0","article-title":"High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.","volume":"768","author":"Bakhtiar","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R40-14-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"},{"key":"R41-14-20210129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"R42-14-20210129","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"R43-14-20210129","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R44-14-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R46-14-20210129","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"R47-14-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"R48-14-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"R49-14-20210129","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"R50-14-20210129","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","article-title":"Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.","volume":"41","author":"Zalcberg","year":"2005","journal-title":"Eur J Cancer"},{"key":"R51-14-20210129","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","article-title":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"R52-14-20210129","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"R53-14-20210129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"R54-14-20210129","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R55-14-20210129","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.","volume":"358","author":"van Oosterom","year":"2001","journal-title":"Lancet"},{"key":"R56-14-20210129","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.","volume":"26","author":"Gibbons","year":"2008","journal-title":"J Clin Oncol"},{"key":"R57-14-20210129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2007.11.0304","article-title":"Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.","volume":"26","author":"Ramanathan","year":"2008","journal-title":"J Clin Oncol"},{"key":"R58-14-20210129","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","article-title":"Population pharmacokinetics I: background, concepts, and models.","volume":"38","author":"Ette","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R59-14-20210129","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","article-title":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.","volume":"54","author":"Dutreix","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"R60-14-20210129","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","article-title":"Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.","volume":"50","author":"Goh","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R61-14-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","article-title":"Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature.","volume":"33","author":"Guastafierro","year":"2009","journal-title":"Leuk Res"},{"key":"R62-14-20210129","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"R63-14-20210129","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"R64-14-20210129","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"R66-14-20210129","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R67-14-20210129","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2007-04-087874","article-title":"Use of therapeutic drug monitoring in CML patients on imatinib.","volume":"110","author":"Mahon","year":"2007","journal-title":"Blood"},{"key":"R68-14-20210129","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"R69-14-20210129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e31823cdec9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:18Z","timestamp":1786047858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201202000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31823cdec9","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}